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: Process For The Preparation of N-(5-chloropyridin-2-yl)-2-[4-(N,N

Process for the preparation of N-(5-chloropyridin-2-yl)-2-[4-(N,Ndimethylcarbamimidoyl)-benzoylamino]-5-methoxybenzamide and its
pharmaceutically acceptable salts
5

Field of the Invention:
The present invention provides a process for the preparation of N-(5-chloropyridin-2yl)-2[4-(N,N-dimethylcarbamimidoyl)-benzoylamino]-5-methoxybenzamide represented by
the following structural formula-1 and pharmaceutically acceptable salts thereof.

Formula-1

10

The present invention also provides novel crystalline polymorph of N-(5chloropyridin-2-yl)-2[4-(N,N-dimethylcarbamimidoyl)-benzoylamino]-5-methoxy
benzamide succinate compound of formula-1b and process for its preparation.

15

Background of the Invention:
N-(5-chloropyridin-2-yl)-2[4-(N,N-dimethylcarbamimidoyl)-benzoylamino]-5methoxybenzamide maleate commonly known as Betrixaban maleate is a factor Xa (FXa)
inhibitor indicated for the prophylaxis of venous thromboembolism m (VTE) in adult patients
hospitalized for an acute medical illness who are at risk for thromboembolic complications

20

due to moderate or severe restricted mobility and other risk factors for VTE. Betrixaban
maleate was developed by Portola pharm Inc. This drug was approved by United States Food
and Drug administration (USFDA) on June 23, 2017 and is marketed under the brand name
BEVYXXA in USA.

1
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N-(5-chloropyridin-2-yl)-2[4-(N,N-dimethylcarbamimidoyl)-benzoylamino]-5methoxybenzamide and its process for preparation is first described in US6376515B2.
N-(5-chloropyridin-2-yl)-2[4-(N,N-dimethylcarbamimidoyl)-benzoylamino]-5methoxybenzamide maleate, its crystalline polymorph and process for its preparation is first
5

described in US7598276B2.
Salts are formed when a compound that is ionized in solution forms a strong ionic
interaction with an oppositely charged counter-ion, leading to crystallization of the salt form.
All acidic and basic compounds can participate in salt formation.
Salt formation offers many advantages to the pharmaceutical products as it can

10

improve the solubility, dissolution rate, permeability, and efficacy of the drug. The primary
purpose of forming a salt is to increase the amount of drug in solution. Salt forms of drugs
have significant effects on physicochemical properties of the drug influencing its quality,
safety, and performance.

15

The

present

invention

provides

N-(5-chloropyridin-2-yl)-2[4-(N,N-

dimethylcarbamimidoyl)-benzoylamino]-5-methoxybenzamide

succinate

compound

of

formula-1b, its crystalline polymorph and process for preparation thereof.
The present invention further provides a process for the preparation of N-(5chloropyridin-2-yl)-2[4-(N,N-dimethylcarbamimidoyl)-benzoylamino]-520

methoxybenzamide maleate compound of formula-1a.
Brief description of the invention:
The first aspect of the present invention is to provide a process for the preparation of
compound of formula-1a.

25

The second aspect of the present invention is to provide a novel crystalline
polymorph of compound of formula-1b.
The third aspect of the present invention is to provide a process for the preparation of
compound of formula-1b.
The fourth aspect of the present invention is to provide a crystalline polymorph of

30

compound of formula-8a and process for its preparation.
2
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Brief Description of the Drawings:
Figure-1: Illustrates the PXRD pattern of crystalline succinate salt compound of formula-1b
Figure-2: Illustrates the PXRD pattern of compound of formula-1
Figure-3: Illustrates the PXRD pattern of compound of formula-1
5

Figure-4: Illustrates the PXRD pattern of compound of formula-1
Figure-5: Illustrates the PXRD pattern of compound of formula-8a
Figure-6: Illustrates the PXRD pattern of compound of formula-1a

Detailed description of the Invention:
10

The “solvent” used in the present invention can be selected from but not limited to
“hydrocarbon solvents” such as n-pentane, n-hexane, n-heptane, cyclohexane, petroleum
ether, benzene, toluene, xylene and the like; “ether solvents” such as dimethyl ether, diethyl
ether, diisopropyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 1,4dioxane and the like; “ester solvents” such as methyl acetate, ethyl acetate, n-propyl acetate,

15

isopropyl acetate, n-butyl acetate, isobutyl acetate, tert-butyl acetate and the like; “polaraprotic solvents” such as dimethylacetamide, dimethylformamide, dimethylsulfoxide, Nmethylpyrrolidone (NMP) and the like; “chloro solvents” such as dichloromethane,
dichloroethane, chloroform, carbon tetrachloride and the like; “ketone solvents” such as
acetone, methyl ethyl ketone, methyl isobutyl ketone and the like; “nitrile solvents” such as

20

acetonitrile, propionitrile, isobutyronitrile and the like; “alcohol solvents” such as methanol,
ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol, 2-butanol, tert-butanol, ethane-1,2diol, propane-1,2-diol and the like; “polar solvents” such as water; formic acid, acetic acid
and the like or mixture of any of the afore mentioned solvents.
The “base” used in the present invention can be selected from but not limited to

25

“inorganic bases” selected from “alkali metal carbonates” such as sodium carbonate,
potassium carbonate, lithium carbonate, cesium carbonate and the like; “alkali metal
bicarbonates” such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate,
cesium bicarbonate and the like; “alkali metal hydroxides” such as sodium hydroxide,
potassium hydroxide, lithium hydroxide, cesium hydroxide and the like; “alkali metal

30

hydrides” such as sodium hydride, potassium hydride, lithium hydride and the like; “alkali
3
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metal amides” such as sodium amide, potassium amide, lithium amide and the like;
ammonia; “organic bases” like “alkali metal alkoxides” such as sodium methoxide, sodium
ethoxide, potassium methoxide, potassium ethoxide, lithium methoxide, lithium ethoxide,
sodium tert.butoxide, potassium tert.butoxide, lithium tert.butoxide and the like; alkali metal
5

and alkali earth metal salts of acetic acid such as sodium acetate, potassium acetate,
magnesium acetate, calcium acetate and the like; dimethylamine, diethylamine, diisopropyl
mine, diisopropylethylamine (DIPEA), diisobutylamine, trimethylamine, triethylamine,
triisopropylamine, tributylamine, tert.butyl amine, pyridine, piperidine, 4-dimethylamino
pyridine (DMAP), quinoline, imidazole, N-methylimidazole, 1,8-diazabicyclo[5.4.0] undec-

10

7-ene

(DBU),

1,5-diazabicyclo[4.3.0]non-5-ene (DBN),

dimethylaniline,

N-methyl

morpholine (NMM), 1,4-diazabicyclo[2.2.2]octane (DABCO), 2,6-lutidine and the like;
“organolithium bases” such as methyl lithium, n-butyl lithium, lithium diisopropylamide
(LDA) and the like; “organosilicon bases” such as lithium hexamethyldisilazide (LiHMDS),
sodium hexamethyldisilazide (NaHMDS), potassium hexamethyldisilazide (KHMDS) and
15

the like or mixtures thereof.
The “coupling agent” used in the present invention can be selected from but not
limited to N,N'-dicyclohexylcarbodiimide (DCC), N,N’-diisopropyl carbodiimide (DIC), 1ethyl-3-(3-dimethylaminopropyl)carbodiimide

20

carbonyldiimidazole

(CDI),

pyridinium

hexafluorophosphate

3-oxid

tetramethyluronium

hydrochloride

(EDC.HCl),

N,N’-

1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]
(HATU),

hexaﬂuorophosphate

2-(1H-benzotriazol-1-yl)-1,1,3,3-

(HBTU),

1H-benzotriazolium

[bis(dimethylamino)methylene]-5chloro-hexafluorophosphate

(1-)

3-oxide

1-

(HCTU),

alkyl/aryl/aralkyl chloroformates such as methyl chloroformate, ethyl chloroformate,
isopropyl chloroformate, phenyl chloroformate, benzylchloroformate and the like;
25

diphenylphosphoroazidate

(DPPA),

thionyl

chloride,

oxalyl

chloride,

phosphorous

oxychloride, phosphorous pentachloride, 4-methyl-2-oxopentanoyl chloride (i-BuCOCOCl),
(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium

hexafluorophosphate

(BOP),

benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), alkyl/aryl
sulfonyl
30

chlorides

such

as

methanesulfonyl

chloride,

ethanesulfonyl

chloride,

benzenesulfonyl chloride, p-toluenesulfonyl chloride and the like optionally in combination
4
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with 1-hydroxy-7-azatriazole (HOAt), 1-hydroxybenzotriazole (HOBt), 1-hydroxy-1H-1,2,3triazole-4-carboxylate

(HOCt),

O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium

tetrafluoroborate (TBTU), N-hydroxysuccinamide (HOSu), N-hydroxysulfosuccinimide
(Sulfo-NHS) and the like.
5
The first aspect of the present invention provides a process for the preparation of
compound of formula-1a, comprising;
a)

treating acid-addition salt of compound of formula-1 with maleic acid in a solvent,
wherein the acid is not maleic acid,

10

b) optionally isolating the compound of formula-1a from the reaction mixture.
The acid in the acid-addition salt can be selected from but not limited to succinic acid,
oxalic acid, acetic acid, pivalic acid, hydrochloric acid, sulfuric acid, phosphoric acid, lactic
acid, phenoxyacetic acid, propionic acid, adepic acid, ascorbic acid, substituted/unsubstituted

15

alkyl/aryl sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic
acid, p-toluenesulfonic acid, naphthalenesulfonic acid, camphorsulfonic acid, gluconic acid,
tartaric acid, citric acid, fumaric acid, glycolic acid, benzoic acid, malic acid, malonic acid,
mandelic acid and the like; and the solvent can be selected from alcohol solvents, polar
solvents, ester solvents, nitrile solvents, polar-aprotic solvents, ketone solvents, chloro

20

solvents or mixtures thereof.
In an embodiment of the present invention, the acid is preferably succinic acid.
An embodiment of the present invention provides a process for the preparation of
compound of formula-1a, comprising;

25

a)

treating succinate salt compound of formula-1b with maleic acid in a solvent,

b) optionally isolating the compound of formula-1a from the reaction mixture.
Another embodiment of the present invention provides a process for the preparation
of compound of formula-1a, comprising;
30

a)

treating succinate salt compound of formula-1b with maleic acid in a solvent,

b) combining the reaction mixture with an anti-solvent to provide compound of formula-1a.
5
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The solvent can be selected from alcohol solvents, polar solvents, ester solvents,
nitrile solvents, polar-aprotic solvents, ketone solvents, chloro solvents or mixtures thereof.
The anti-solvent can be selected from but not limited to hydrocarbon solvents, ether
solvents or mixtures thereof.
5
In an embodiment of the present invention, the acid-addition salt of N-(5chloropyridin-2-yl)-2[4-(N,N-dimethylcarbamimidoyl)-benzoylamino]-5-methoxy
benzamide compound of formula-1 is prepared by treating compound of formula-1 with an
acid in a solvent.
10
Wherein, the acid is selected from but not limited to succinic acid, oxalic acid, acetic
acid, pivalic acid, hydrochloric acid, sulfuric acid, phosphoric acid, lactic acid,
phenoxyacetic acid, propionic acid, adepic acid, ascorbic acid, substituted/unsubstituted
alkyl/aryl sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic
15

acid, p-toluenesulfonic acid, naphthalenesulfonic acid, camphorsulfonic acid, gluconic acid,
tartaric acid, citric acid, fumaric acid, glycolic acid, benzoic acid, malic acid, malonic acid,
mandelic acid; and the solvent is selected from but not limited to alcohol solvents, polar
solvents, ester solvents, nitrile solvents, polar-aprotic solvents, ketone solvents, chloro
solvents or mixtures thereof.

20
The second aspect of the present invention provides a novel crystalline polymorph of
compound of formula-1b. The said novel crystalline polymorph is herein designated as
crystalline form-S.
The crystalline form-S of compound of formula-1b is characterized by its PXRD
25

pattern having peaks at 5.9, 9.4, 12.5, 14.9, 15.2, 17.1, 21.3, 24.4, 25.1, 26.1 and 27.8 ± 0.2°
of 2-theta. The crystalline form-S is further characterized by its PXRD pattern having peaks
at 6.1, 7.6, 11.8, 15.7, 18.1, 18.7, 18.9, 19.6 and 27.3 ± 0.2° of 2-theta.
In another embodiment, the crystalline form-S of compound of formula-1b is further

30

characterized by its PXRD pattern as shown in figure-1.
6
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The third aspect of the present invention provides a process for the preparation of
compound of formula-1b, comprising;
a)

treating compound of formula-1 with succinic acid in a solvent,

b) optionally isolating the succinate salt compound of formula-1b.
5
Wherein, the solvent can be selected from alcohol solvents, polar solvents, ester
solvents, nitrile solvents, polar-aprotic solvents, ketone solvents, chloro solvents or mixtures
thereof.
In the present invention, isolating the compound(s) from the reaction mixture
10

wherever required can be carried out by removal of solvent from the reaction mixture.
Suitable techniques which may be used for the removal of solvent from the reaction mixture
includes but not limited to evaporation, evaporation under reduced pressure, flash
evaporation, vacuum drying, concentrating the reaction mixture, atmospheric distillation,
distillation under reduced pressure, distillation by using a rotational distillation device such

15

as a Buchi Rotavapor, agitated thin film drying (ATFD), melt extrusion, spray drying, freeze
drying (lyophilization), spray-freeze drying, addition of suitable anti-solvent to the reaction
mixture followed by filtration of the precipitated solid, cooling the clear solution to lower
temperatures to precipitate the solid followed by filtration of the reaction mixture or by any
other suitable techniques known in the art.

20
An embodiment of the present invention provides a process for the preparation of
compound of formula-1b, comprising;
a)

treating compound of formula-1 with succinic acid in a solvent,

b) combining the reaction mixture with an anti-solvent to provide compound of formula-1b.
25
Wherein, the solvent can be selected from alcohol solvents, polar solvents, ester
solvents, nitrile solvents, polar-aprotic solvents, ketone solvents, chloro solvents or mixtures
thereof.
The anti-solvent can be selected from but not limited to hydrocarbon solvents, ether
30

solvents or mixtures thereof.
7
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The fourth aspect of the present invention provides a crystalline polymorph of
compound of formula-8a and process for its preparation.
The crystalline polymorph of compound of formula-8a is characterized by its PXRD
5

pattern having peaks at 5.7, 10.2, 12.4, 13.5, 15.8, 19.2, 23.8, 25.1, 25.3, 26.7, 28.0 and 30.1
± 0.2° of 2-theta.
The crystalline polymorph of compound of formula-8a is further characterized by its
PXRD pattern having peaks at 6.1, 11.5, 19.5, 21.4, 21.6, 29.1, 32.0 and 35.1 ± 0.2° of
2-theta.

10
The crystalline polymorph of compound of formula-8a of the present invention is
further characterized by its PXRD pattern as shown in figure-5.
An embodiment of the present invention provides a process for the preparation of
15

compound of formula-8a, comprising;
a)

treating compound of formula-8 with a HCl source optionally in presence of a solvent,

b) optionally isolating compound of formula-8a from the reaction mixture.

Wherein, the HCl source can be selected from but not limited to conc.HCl, aqueous
20

HCl, HCl gas, ethyl acetate-HCl, isopropyl acetate-HCl, methanol-HCl, ethanol-HCl,
isopropanol-HCl, HCl in dioxane and the like.
The solvent can be selected from but not limited to hydrocarbon solvents, ether
solvents, ester solvents, polar-aprotic solvents, chloro solvents, ketone solvents, nitrile
solvents, alcohol solvents, polar solvents or any of the mixtures thereof.

25
The compound of formula-1 utilized in the present invention can be prepared by any
of the processes known in the art.

30
8
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In one embodiment, the compound of formula-1 can be prepared by the following
process, which comprising;
a)

reacting 5-methoxy-2-nitrobenzoic acid compound of formula-2

5

Formula-2
with 5-chloropyridin-2-amine compound of formula-3

Formula-3
in presence of a coupling reagent and/or a base in a solvent to provide N-(5chloropyridin-2-yl)-5-methoxy-2-nitrobenzamide compound of formula-4,

10

Formula-4
b) reducing compound of formula-4 with a reducing agent in a solvent to provide 2-aminoN-(5-chloropyridin-2-yl)-5-methoxybenzamide compound of formula-5,

15
Formula-5
c)

reacting compound of formula-5 with 4-cyanobenzoic acid compound of formula-6

Formula-6

9
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in presence of a coupling agent and/or a base in a solvent to provide N-(5-chloropyridin2-yl)-2-(4-cyanobenzamido)-5-methoxybenzamide compound of formula-8,

Formula-8
5

d) optionally converting compound of formula-8 to its hydrochloride salt of formula-8a,
e)

reacting compound of formula-8 or its hydrochloride salt with dimethylamine in
presence of Grignard reagent in a solvent to provide compound of formula-1 .

Wherein, the coupling agent in step-a) and step-c) can be selected from those defined
10

above; the base can be selected from organic bases, inorganic bases or mixtures thereof;
The reducing agent in step-b) can be selected from but not limited to metals such as
Pd, Pt, Rh, Ni, Raney Ni optionally under hydrogen gas pressure; the metal is optionally
supported on activated charcoal; Fe, Fe in acidic media like HCl, acetic acid, NH4Cl; SnHCl, stannous chloride (SnCl2), Zn in acidic media like HCl, acetic acid, NH4Cl, Zinc dust,

15

sodium borohydride, lithium borohydride, lithium aluminium hydride, sodium aluminium
hydride, diborane, hydrazine hydrate, sodium dithionite, sodium sulfide, ammonium sulfide,
Na-Hg/H2, borane-tetrahydrofuran, Platinum oxide, thiourea dioxide and the like;
The Grignard reagent in step-e) can be selected from but not limited to alkyl
magnesium halides(C1-C6alkyl), alkenyl(C1-C3alkenyl)magnesium halides, alkynyl(C1-C6

20

alkynyl)magnesium halides, aryl magnesium halides, allyl magnesium halides and the like;
The solvent in step-a) to step-e) wherever necessary can be selected from but not
limited to hydrocarbon solvents, ether solvents, ester solvents, polar-aprotic solvents, chloro
solvents, ketone solvents, nitrile solvents, alcohol solvents, polar solvents, formic acid, acetic
acid or any of the mixtures thereof.

25
10
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The compound of formua-1 of the present invention can be further treated with an
acid optionally in presence of a solvent to provide corresponding acid-addition salt.
Wherein, the acid can be selected from but not limited to “inorganic acids” such as
hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like;
5

“organic acids” such as formic acid, acetic acid, propionic acid, butyric acid, valeric acid,
glycolic acid, pyruvic acid, capric acid, malonic acid, tartaric acid, citric acid, succinic acid,
mandelic acid, cinnamic acid, adepic acid, ascorbic acid, lactic acid, nicotinic acid, pivalic
acid, trifluoroacetic acid, benzoic acid, salicylic acid, 4-hydroxybenzoic acid, oxalic acid,
octanoic acid, malic acid, maleic acid, fumaric acid, phenoxyacetic acid, gluconic acid,

10

substituted/unsubstituted

alkyl/aryl

sulfonic

acids

such

as

methanesulfonic

acid,

ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid,
camphorsulfonic acid and the like.
The solvent can be selected from but not limited to hydrocarbon solvents, ether
solvents, ester solvents, polar-aprotic solvents, chloro solvents, ketone solvents, nitrile
15

solvents, alcohol solvents, polar solvents or any of the mixtures thereof.

The compound of formula-2, compound of formula-3 and compound of formula-6
which are utilized in the above process can be prepared by any of the processes known in the
art or they can be procured from any commercial sources available.
20
The PXRD analysis was carried out by using BRUKER/D8 ADVANCE X-Ray
diffractometer using CuKα radiation of wavelength 1.5406A° and at a continuous scan speed
of 0.03°/min.
The compound of formula-1a and compound of formula-1b produced by the
25

processes of the present invention are having purity of greater than 98%, preferably greater
than 99% by HPLC and are useful for the preparation of various pharmaceutical
compositions formulated in a manner suitable for the route of administration to be used
where at least a portion of compound is present in the composition in particular polymorphic
form mentioned. Such pharmaceutical compositions may comprise any of the said

30

compounds in the composition in a range of between 0.005% and 100% (wt/wt), with the
11
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balance of the pharmaceutical composition comprising additional substances such as
excipients, diluents, lubricants, binders, wetting agents, disintegrating agents, glidants,
sweetening agents, flavoring agents, emulsifying agents, solubilizing agents, pH buffering
agents, perfuming agents, surface stabilizing agents, suspending agents and other
5

conventional pharmaceutically inactive agents.
HPLC Method of Analysis:
The compound of formula-1a and compound of formula-1b of the present invention
were analyzed by HPLC under the following conditions;

10

Apparatus: A liquid chromatographic system equipped with variable wavelength UV
detector; Column: Kinetex Biphenyl, 250 mm x 4.6 mm, 5 µm; Wavelength: 235 nm;
Column temperature: 30°C; Auto sampler temperature: 25°C; Injection volume: 5 µL;
Diluent: Acetonitrile: Water (90:10 v/v); Elution: Gradient; Buffer: Accurately transfer 1000
mL of milli-Q-water into a suitable clean and dry beaker. Transfer accurately 2.72 g of

15

Potassium dihydrogen phosphate into the above 1000 mL of Milli-Q-water and sonicate to
dissolve. Adjust its pH to 3.5±0.05 with dil. Ortho phosphoric acid (85%). Filter this solution
through 0.22 µm Durapore PVDF filter paper and sonicate to degas it. Mobile phase-A:
Buffer (100%); Mobile phase-B: Accurately transfer 800 mL of Acetonitrile and 200 mL of
Water into a 1000 mL Mobile phase bottle, mix well and sonicate to degas it.

20
An embodiment of the present invention provides the use of compound of formula-1a
or compound of formula-1b of the present invention for the preparation of pharmaceutical
formulations.
The other embodiment of the present invention provides pharmaceutical composition
25

comprising compound of formula-1a or compound of formula-1b of the present invention
and at least one pharmaceutically acceptable excipient.
The another embodiment of the present invention provides method of treating a
patient in need thereof comprising administering to the said patient a therapeutically effective
amount of compound of formula-1a or compound of formula-1b of the present invention.

12
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The compound of formula-1a and compound of formula-1b produced by the
processes of the present invention are having particle size distribution of D90 less than 500
µm, preferably less than 250 µm, more preferably less than 100 µm.
An embodiment of the present invention provides compound of formula-1a with
5

particle size distribution of D90 less than 50 µm, preferably less than 20 µm, more preferably
less than 15 µm.

Particle size distribution (PSD) method of analysis:
The particle size distribution analysis was carried out by using Malvern Mastersizer
10

3000 instrument.

The compound of formula-1a and compound of formula-1b produced by the
processes of the present invention can be further micronized or milled to get desired particle
size to achieve desired solubility profile based on different forms of pharmaceutical
15

composition requirements. Techniques that may be used for particle size reduction includes
but not limited to single or multi-stage micronization using cutting mills, pin/cage mills,
hammer mills, jet mills, fluidized bed jet mills, ball mills and roller mills. Milling or
micronization may be performed before drying or after drying of the product.

20

25

30
13
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The present invention is schematically represented below.
Scheme-1:

5

10

15

20

25

14
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The best mode of carrying out the present invention is illustrated by the below
mentioned examples. These examples are provided as illustration only and hence should not
be construed as limitation to the scope of the invention.
5

Examples:
Example-1:

Preparation

of

N-(5-chloropyridin-2-yl)-5-methoxy-2-nitrobenzamide

(Formula-4)
A mixture of 5-methoxy-2-nitrobenzoic acid compound of formula-2 (50 gm) and
acetonitrile (250 ml) was stirred for 10 min at 25-30°C. 5-Chloropyridin-2-amine compound
10

of formula-3 (32.6 gm) was added to the reaction mixture at 25-30°C and stirred for 10 min
at the same temperature. Pyridine (61.46 ml) was added to the reaction mixture at 25-30°C
and stirred for 10 min at the same temperature. Cooled the reaction mixture to 15-20°C,
phosphorous oxychloride (28.36 ml) was slowly added to it and stirred for 3 hr at the same
temperature. Cooled the reaction mixture to 5-10°C, water (500 ml) was slowly added to it

15

and stirred for 2 hr at the same temperature. Filtered the solid, washed with water and dried
to get the title compound. Yield: 72.0 gm; M.R.: 165.7-168.0°C.
Example-2: Preparation of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide
(Formula-5)

20

A mixture of compound of formula-4 (100 gm) and acetic acid (1 Lt) was stirred for
10 min at 25-30°C. Heated the reaction mixture to 50-55°C, Iron powder (136.02 gm) was
added lot wise to it and stirred for 2 hr at the same temperature. Ethyl acetate and water were
added to the reaction mixture at 50-55°C and stirred the reaction mixture for 10 min at the
same temperature. Hyflow was added to the reaction mixture at 50-55°C and stirred for

25

10 min at the same temperature. Filtered the reaction mixture and washed the hyflow bed
with ethyl acetate. Cooled the filtrate to 25-30°C, water was added to it and stirred for 15 min
at the same temperature. Both the organic and aqueous layers were separated, aqueous
sodium carbonate solution was added to the organic layer and stirred for 30 min. Filtered the
reaction mixture through Hyflow bed and washed the hyflow bed with ethyl acetate. Both the

30

organic and aqueous layers were separated and washed the organic layer with water. Distilled
off the solvent completely from the organic layer under reduced pressure and expelled the
15
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reaction mixture with nitrogen gas. Toluene (600 ml) was added to the obtained compound at
25-30°C and stirred for 10 min at the same temperature. Heated the reaction mixture to
80-85°C and stirred for 30 min at the same temperature. Cooled the reaction mixture to
25-30°C and stirred for 30 min at the same temperature. Water (600 ml) was slowly added to
5

the reaction mixture at 25-30°C and stirred for 1 hr at the same temperature. Filtered the
solid, washed with toluene and water and dried to get the title compound.
Yield: 66.4 gm; M.R.: 129.2-130.4°C.
Example-3:

10

Preparation

of

N-(5-chloropyridin-2-yl)-2-(4-cyanobenzamido)-5-

methoxybenzamide hydrochloride (Formula-8a)
A mixture of 4-cyanobenzoic acid compound of formula-6 (63.56 gm) and thionyl
chloride (300 ml) was heated to 80-85°C under nitrogen atmosphere and stirred for 3 hr at the
same temperature. Distilled the reaction mixture under nitrogen atmosphere and co-distilled
with toluene. Cooled the reaction mixture to 25-30°C and toluene (600 ml) was added to it.

15

The obtained reaction mixture was slowly added to a mixture of compound of formula-5
(100 gm), toluene (1.5 Lt) and triethylamine (150.15 ml) at 25-30°C under nitrogen
atmosphere and stirred for 4 hr at the same temperature. A mixture of water (1 Lt) and
methanol (1 Lt) was added to the reaction mixture at 25-30°C and stirred for 1 hr at the same
temperature. Filtered the solid, washed with aqueous methanol and dried the material. A

20

mixture of tetrahydrofuran (1 Lt) and methanol (1 Lt) was added to the obtained compound
at 25-30°C. Heated the reaction mixture to 60-65°C and stirred for 1 hr at the same
temperature. Cooled the reaction mixture to 25-30°C and stirred for 1 hr at the same
temperature. Filtered the solid, washed with a mixture of tetrahydrofuran and methanol at
25-30°C and dried the material. Ethyl acetate (2 Lt) was added to the obtained compound at

25

25-30°C. Ethyl acetate-HCl (300 ml) was slowly added to the reaction mixture at 25-30°C
and stirred for 1 hr at the same temperature. Filtered the solid, washed with ethyl acetate and
dried the material to get the title compound. The PXRD pattern of the obtained compound is
shown in figure-5. Yield: 120.0 gm; M.R.: 197.7-199.2ºC.

30
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Example-4: Preparation of compound of formula-1b
2M Dimethylamine solution (1.18 Lt) was slowly added to pre-cooled 3M methyl
magnesium chloride solution (789.5 ml) at 5-10°C and stirred the reaction mixture for 1 hr at
the same temperature. The obtained reaction mixture was slowly added to a pre-cooled
5

mixture of compound of formula-8a (100 gm) and tetrahydrofuran (1 Lt) at 5-10°C and
stirred for 2 hr at the same temperature. Aqueous acetic acid solution (350 ml acetic acid in
350 ml water) was added to the reaction mixture at 5-10°C and stirred for 15 min at the same
temperature. Heated the reaction mixture to 60-65°C and distilled the reaction mixture under
reduced pressure. Water (1 Lt) was added to the reaction mixture at 25-30°C and stirred for

10

15 min at the same temperature. Filtered the solid, washed with water and dried.
The PXRD pattern of the obtained compound is shown in figure-2.
Acetone (900 ml) was added to the obtained compound at 25-30°C. Triethylamine (50 ml)
was slowly added to the reaction mixture at 25-30°C and stirred for 2 hr at the same
temperature. Filtered the solid and washed with acetone.

15

The PXRD pattern of the obtained compound is shown in figure-3.
Toluene (500 ml) was added to the obtained compound at 25-30°C. Heated the reaction
mixture to 80-85°C, dimethyl sulfoxide (600 ml) was slowly added to it and stirred for
15 min at the same temperature. Cooled the reaction mixture to 25-30°C, toluene (1.2 Lt)
was slowly added to it and stirred for 4 hr at the same temperature. Filtered the solid, washed

20

with toluene and dried the compound. PXRD of obtained compound is shown in figure-4.
A mixture of dichloromethane (800 ml) and methanol (200 ml) was added to the obtained
compound at 25-30°C. Aqueous sodium carbonate solution (450 gm of sodium carbonate in
1.5 Lt of water) was slowly added to the reaction mixture at 25-30°C and stirred for 2 hr at
the same temperature. Both the organic and aqueous layers were separated and extracted the

25

aqueous layer with a mixture of dichloromethane and methanol. Combined the organic
layers, succinic acid (31.96 gm) was added to it at 25-30°C and stirred for 45 min at the same
temperature. Methyl tert-butyl ether (500 ml) was added to the reaction mixture at 25-30°C
and stirred for 2 hr at the same temperature. Filtered the solid, washed with methyl tert-butyl
ether and dried to get the title compound. The PXRD pattern of the obtained compound is

30

shown in figure-1. Yield: 60.0 gm; Purity by HPLC: 99.86%.
17
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Example-5: Preparation of compound of formula-1a
A mixture of compound of formula-1b (5 gm), maleic acid (1.2 gm), isopropyl
alcohol (35 ml) and water (5 ml) was heated to 60-65°C. Cooled the reaction mixture to
25-30°C, methyl tert-butyl ether (115 ml) was slowly added to it and stirred for 2 hr at the
5

same temperature. Filtered the solid, washed with methyl tert-butyl ether and dried to get the
title compound. The PXRD pattern of the obtained compound is shown in figure-6.
Yield: 4.0 gm; Purity by HPLC: 99.87%.
Particle size distribution: D(0.1) is 4.69 µm; D(0.5) is 16.9 µm; D(0.9) is 52.8 µm.

10

Example-6: Preparation of compound of formula-1b
2M Dimethylamine solution in tetrahydrofuran (132 Lt) was slowly added to precooled methyl magnesium chloride solution (58 Lt) at 5-10°C and stirred the reaction
mixture for 1 hr at the same temperature. The obtained reaction mixture was slowly added to
a pre-cooled mixture of compound of formula-8a (11 Kg) and tetrahydrofuran (110 Lt) at 5-

15

10°C and stirred for 3 hr at the same temperature. Aqueous acetic acid solution (38.5 Lt of
acetic acid in 38.5 Lt of water) was slowly added to the reaction mixture at 5-10°C and
stirred for 15 min at the same temperature. Heated the reaction mixture to 65-70°C and
distilled the reaction mixture under reduced pressure. Water (55 Lt) was added to the reaction
mixture at 25-30°C and stirred for 30 min at the same temperature. Filtered the solid, washed

20

with water and dried. Yield: 28.8 Kg.
Acetone (99 Lt) was added to the obtained compound at 25-30°C. Triethylamine (4 Kg) was
slowly added to the reaction mixture at 25-30°C and stirred for 2 hr at the same temperature.
Filtered the solid, washed with acetone and spin dried the material. Yield: 24.8 Kg.
Toluene (110 Lt) and dimethyl sulfoxide (110 Lt) were added to the obtained compound at

25

25-30°C. Heated the reaction mixture to 80-85°C and stirred for 15 min at the same
temperature. Cooled the reaction mixture to 25-30°C, toluene (220 Lt) was slowly added to it
and stirred for 8 hr at the same temperature. Filtered the solid, washed with toluene and spin
dried the compound. Yield: 21.6 Kg.
Toluene (55 Lt) and dimethyl sulfoxide (55 Lt) were added to the obtained compound at 25-

30

30°C. Heated the reaction mixture to 80-85°C and stirred for 15 min at the same temperature.
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https://www.tdcommons.org/dpubs_series/3969

19

: Process For The Preparation of N-(5-chloropyridin-2-yl)-2-[4-(N,N

Cooled the reaction mixture to 25-30°C, toluene (165 Lt) was slowly added to it and stirred
for 8 hr at the same temperature. Filtered the solid, washed with toluene and dried the
compound. Yield: 15.1 Kg.
A mixture of dichloromethane (88 Lt) and methanol (22 Lt) was added to the obtained
5

compound at 25-30°C. Cooled the reaction mixture to 10-15°C, aqueous sodium carbonate
solution (24.8 Kg of sodium carbonate in 165 Lt of water) was slowly added to it and stirred
for 30 min at the same temperature. Both the organic and aqueous layers were separated and
extracted the aqueous layer with a mixture of dichloromethane and methanol. Combined the
organic layers and cooled to 10-15°C. A solution of succinic acid (4.4 Kg) in methanol (33

10

Lt) was added to the organic layer at 10-15°C and stirred the reaction mixture for 45 min at
the same temperature. Methyl tert-butyl ether (55 Lt) was added to the reaction mixture at
10-15°C and stirred for 4 hr at the same temperature. Filtered the solid, washed with methyl
tert-butyl ether and dried to get the title compound.
Yield: 9 Kg. Succinic acid content by potentiometry: 18.1% w/w; Purity by HPLC: 99.83%.

15

Example-7: Preparation of compound of formula-1a
A mixture of compound of formula-1b (8 Kg), maleic acid (1.92 Kg), isopropyl
alcohol (56 Lt) and water (8 Lt) was heated to 65-70°C and stirred for 30 min at the same
temperature. Cooled the reaction mixture to 25-30°C, methyl tert-butyl ether (120 Lt) was

20

slowly added to it and stirred for 4 hr at the same temperature. Filtered the solid, washed with
methyl tert-butyl ether and spin dried the material. The obtained compound was added to a
mixture of isopropyl alcohol (45 Lt) and water (6.4 Lt) at 25-30°C. Heated the reaction
mixture to 65-70°C and stirred for 30 min at the same temperature. Filtered the reaction
mixture and washed with hot isopropyl alcohol. Cooled the filtrate to 25-30°C and methyl

25

tert.butyl ether (96 Lt) was added to it and stirred the reaction mixture for 2 hr at the same
temperature. Filtered the precipitated solid, washed with methyl tert.butyl ether and dried the
material to get the title compound. The PXRD pattern of the obtained compound is similar to
figure-6. Yield: 5.72 Kg; Purity by HPLC: 99.88%.

30
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Drawings

5

Figure-1

Figure-2
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Figure-3
5

Figure-4
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Figure-5

5
Figure-6
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